Surgical considerations in tumor-infiltrating lymphocyte therapy: Challenges and opportunities Guidelines


Authors: Kirane, A.; Lee, D.; Ariyan, C.
Title: Surgical considerations in tumor-infiltrating lymphocyte therapy: Challenges and opportunities
Abstract: Adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is a promising personalized immunotherapy approach, spearheaded by Dr. Steven Rosenberg, targeting various cancer types. Despite initial challenges in TIL production, recent advancements have showcased its superiority to immune checkpoint blockade in metastatic melanoma, even after anti-PD-1 therapy failure. The expedited manufacturing process, now around 3 weeks, coupled with the US Food and Drug Administration approval of lifileucel in 2024, is poised to propel TIL therapy into mainstream oncology. This commentary delves into the critical surgical aspects of TIL harvesting, emphasizing the integral role of surgeons in ensuring optimal TIL quality, safety, and therapeutic effectiveness. By shedding light on these considerations, this article aims to guide and enhance collaborative efforts in advancing TIL therapy for patients facing limited treatment options. © 2024 The American Society for Transplantation and Cellular Therapy
Keywords: neoplasm; neoplasms; tumor associated leukocyte; lymphocytes, tumor-infiltrating; melanoma; practice guideline; transplantation; immunology; immunotherapy; surgery; cell therapy; therapy; adoptive immunotherapy; immunotherapy, adoptive; procedures; tumor infiltrating lymphocytes; humans; human
Journal Title: Transplantation and Cellular Therapy
Volume: 31
Issue: 3 Suppl.
ISSN: 2666-6375
Publisher: Elsevier Inc.  
Date Published: 2025-03-01
Start Page: S591
End Page: S598
Language: English
DOI: 10.1016/j.jtct.2024.11.015
PUBMED: 40089328
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Charlotte Eielson Ariyan
    154 Ariyan